Last reviewed · How we verify
NCT05060510
The School SPIT Study - COVID-19 Testing in Secondary Schools
NA trial testing Take home saliva kit in SARS-CoV2 Infection in 60 participants. Completed in 30 June 2022.
1 November 2021
Quick facts
| Lead sponsor | The Hospital for Sick Children |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 60 |
| Start date | 14 September 2021 |
| Primary completion | 1 November 2021 |
| Estimated completion | 30 June 2022 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Take home saliva kit
Conditions studied
- SARS-CoV2 Infection — all drugs for SARS-CoV2 Infection →
Sponsor
The Hospital for Sick Children
Who can join
2 and older, any sex, with SARS-CoV2 Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will conduct an evaluation of a program that is being implemented SickKids / Toronto Public health that provides take-home saliva testing kits in schools. Operationally, there is a planned randomization so that all schools have an equitable chance to receive the intervention at various time periods during the planned operational roll-out, which will require a staggered implementation consistent with the stepped-wedge study design. The study will leverage this chance implementation to do a robust evaluation of the public health intervention. Schools that are not being rolled out to week one, will begin in the "control phase" (testing at an assessment center) and transition to the program "intervention phase" (take home saliva kits available at schools) at a randomly assigned time (wedge) over a 6-week period with all schools receiving the program by the end of the study. The investigators will evaluate the impact of the program on SARS-CoV-2 case identification in schools.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05060510
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for SARS-CoV2 Infection
Currently open trials in the same condition.
- NCT05852873 — PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway · Phase 3 · active not recruiting
- NCT04910269 — Outpatient Treatment With Anti-Coronavirus Immunoglobulin · Phase 3 · recruiting
- NCT04830852 — Pediatric COVID Outcomes Study (PECOS) · active not recruiting
- NCT04844242 — MISC COVID-19 Study in Pediatric Population · recruiting
Other The Hospital for Sick Children trials
Trials by the same sponsor.
- NCT07454681 — MRI Assessment of Lung Airways in Cystic Fibrosis: Evaluate MRI's Ability to Detect Changes in Airway Structure . · not yet recruiting
- NCT07452575 — 3D Ultrasound in Hemophilic Ankles · NA · not yet recruiting
- NCT07508826 — AI-assisted Endotracheal Intubation · NA · not yet recruiting
- NCT07345819 — Dexamethasone vs. Placebo in Children and Youth Hospitalized for Orbital Cellulitis · NA · not yet recruiting
- NCT07497178 — MRgFUS for Childhood Epilepsy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05060510 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Hospital for Sick Children
- Last refreshed: 25 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05060510.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing